CONTRATOS DE INVESTIGACIÓN
Contract 29/2019
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
date_range
Duration: from 08 March 2019 to 29 February 2020
(12 months)
Of International (non-EU) scope. It has been granted under a regime of Direct grant.
